Arthur Levinson, formerly of Genentech, has left Roche to avoid any potential conflict of interest in his role as chief executive of Google’s Calico start-up company. Calico recently agreed a $1.5bn alliance with AbbVie, a rival of Roche, to develop treatments for age-related disease. Levinson was appointed by Google last year to head this new biotech venture, having a mission to extend healthy lifespan.
Google’s Calico and AbbVie Collaboration (Reuters)
AbbVie Inc and Calico are each planning to invest $250 million on Calico research facilities and their collaboration on the discovery and development of new medicines.
Pierson, R. (2014). Google’s Calico, AbbVie forge deal against diseases of aging. [Online]: Reuters, September 3rd 2014.
More on Google’s Health Portfolio
Google has purchased Lift Labs, a biotech company which has developed a spoon designed to assist people with Parkinson’s Disease and other conditions involving tremor.
Google buys firm behind spoon for Parkinson’s patients. London: BBC Health News, September 11th 2014.
Possibly also of interest,
Kelion, L. [and] Gallagher, J. (2014). Google is developing cancer and heart attack detector. London: BBC Technology News / BBC Health News, October 28th 2014.
Google’s DeepMind / Royal Free Trust Data-Sharing Agreement
DeepMind, Google’s artificial intelligence division, has been granted access to patient information from the Royal Free, Barnet and Chase Farm hospitals in London. The aim is to use this data to develop an early warning system (the Streams app) for acute kidney injury (AKI). AKI is thought to be a contributory factor behind up to 20% of emergency hospital admissions (and 40,000 deaths per year in the UK); around a quarter of which cases may be preventable.
Wakefield, J. (2016). Google given access to London patient records for research. London: BBC Technology News / BBC Health News, May 3rd 2016.